CA1287801C - Methode de dosage des peptides du collagene humain par immunoessai enzymatique - Google Patents

Methode de dosage des peptides du collagene humain par immunoessai enzymatique

Info

Publication number: CA1287801C
Authority: CA; Canada
Prior art keywords: monoclonal antibody; collagen; type iii; antibody; enzyme
Prior art date: 1986-09-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 530844

Other languages

English (en)

Inventor

Akira Oshima

Kazushi Iwata

Yasuo Bai

Eisaku Matsumoto

Yasuteru Muragaki

Satoshi Miyamoto

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kyowa Pharma Chemical Co Ltd

Original Assignee

Fuji Yakuhin Kogyo KK

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-09-04

Filing date

1987-02-27

Publication date

1991-08-20

1987-02-27 Application filed by Fuji Yakuhin Kogyo KK filed Critical Fuji Yakuhin Kogyo KK

1991-08-20 Application granted granted Critical

1991-08-20 Publication of CA1287801C publication Critical patent/CA1287801C/fr

2008-08-20 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

102000008186 Collagen Human genes 0.000 title claims abstract description 79
108010035532 Collagen Proteins 0.000 title claims abstract description 79
229920001436 collagen Polymers 0.000 title claims abstract description 79
108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 62
238000000034 method Methods 0.000 title claims abstract description 56
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 32
102000004190 Enzymes Human genes 0.000 title claims abstract description 23
108090000790 Enzymes Proteins 0.000 title claims abstract description 23
238000003018 immunoassay Methods 0.000 title claims abstract description 16
239000007790 solid phase Substances 0.000 claims abstract description 16
208000019423 liver disease Diseases 0.000 claims abstract description 11
210000002966 serum Anatomy 0.000 claims description 20
102000001187 Collagen Type III Human genes 0.000 claims description 12
108010069502 Collagen Type III Proteins 0.000 claims description 12
239000007795 chemical reaction product Substances 0.000 claims description 12
102000004266 Collagen Type IV Human genes 0.000 claims description 8
108010042086 Collagen Type IV Proteins 0.000 claims description 8
239000000758 substrate Substances 0.000 claims description 8
102000002734 Collagen Type VI Human genes 0.000 claims description 6
108010043741 Collagen Type VI Proteins 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 5
238000003745 diagnosis Methods 0.000 abstract description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
239000001963 growth medium Substances 0.000 description 25
210000004408 hybridoma Anatomy 0.000 description 14
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
210000004027 cell Anatomy 0.000 description 13
239000011780 sodium chloride Substances 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
229940088598 enzyme Drugs 0.000 description 12
208000019425 cirrhosis of liver Diseases 0.000 description 11
239000000243 solution Substances 0.000 description 11
239000004793 Polystyrene Substances 0.000 description 9
238000005259 measurement Methods 0.000 description 9
229920002223 polystyrene Polymers 0.000 description 9
206010008909 Chronic Hepatitis Diseases 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
206010019755 Hepatitis chronic active Diseases 0.000 description 7
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
239000007853 buffer solution Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000010367 cloning Methods 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
238000002965 ELISA Methods 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
239000012980 RPMI-1640 medium Substances 0.000 description 6
230000003053 immunization Effects 0.000 description 6
238000011534 incubation Methods 0.000 description 6
239000000523 sample Substances 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
206010035226 Plasma cell myeloma Diseases 0.000 description 5
238000002835 absorbance Methods 0.000 description 5
201000000050 myeloid neoplasm Diseases 0.000 description 5
239000007787 solid Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
102000003992 Peroxidases Human genes 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
235000011089 carbon dioxide Nutrition 0.000 description 4
230000016784 immunoglobulin production Effects 0.000 description 4
239000002609 medium Substances 0.000 description 4
108040007629 peroxidase activity proteins Proteins 0.000 description 4
239000008055 phosphate buffer solution Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
206010003445 Ascites Diseases 0.000 description 3
241000283707 Capra Species 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
229910052921 ammonium sulfate Inorganic materials 0.000 description 3
235000011130 ammonium sulphate Nutrition 0.000 description 3
230000027455 binding Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
230000007910 cell fusion Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000005194 fractionation Methods 0.000 description 3
238000002649 immunization Methods 0.000 description 3
238000005497 microtitration Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
210000004988 splenocyte Anatomy 0.000 description 3
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
108091006629 SLC13A2 Proteins 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
229960003896 aminopterin Drugs 0.000 description 2
210000000628 antibody-producing cell Anatomy 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
230000004761 fibrosis Effects 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000012260 resinous material Substances 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
229960005508 8-azaguanine Drugs 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
102000012432 Collagen Type V Human genes 0.000 description 1
108010022514 Collagen Type V Proteins 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102100034866 Kallikrein-6 Human genes 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000004105 Penicillin G potassium Substances 0.000 description 1
108090000279 Peptidyltransferases Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010050808 Procollagen Proteins 0.000 description 1
102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229960001656 amikacin sulfate Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
239000012928 buffer substance Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
244000309466 calf Species 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000007449 liver function test Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
235000019368 penicillin G potassium Nutrition 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
238000005375 photometry Methods 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920006122 polyamide resin Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
229960002385 streptomycin sulfate Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
229960001763 zinc sulfate Drugs 0.000 description 1
229910000368 zinc sulfate Inorganic materials 0.000 description 1

Landscapes

Preparation Of Compounds By Using Micro-Organisms (AREA)

CA 530844 1986-09-04 1987-02-27 Methode de dosage des peptides du collagene humain par immunoessai enzymatique Expired - Fee Related CA1287801C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP61206862A JPH0638081B2 (ja)	1986-09-04	1986-09-04	ヒトコラーゲンペプチドの酵素免疫測定法
JP206862/61(1986)		1986-09-04

Publications (1)

Publication Number	Publication Date
CA1287801C true CA1287801C (fr)	1991-08-20

Family

ID=16530271

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 530844 Expired - Fee Related CA1287801C (fr)	1986-09-04	1987-02-27	Methode de dosage des peptides du collagene humain par immunoessai enzymatique

Country Status (2)

Country	Link
JP (1)	JPH0638081B2 (fr)
CA (1)	CA1287801C (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5834221A (en) *	1987-11-06	1998-11-10	Washington Research Foundation	Assay for type I collagen carboxy-terminal telopeptide analytes
US6027903A (en) *	1987-11-06	2000-02-22	Washington Research Foundation	Kit for detecting analyte indicative of type I collagen resorption in vivo
US6143511A (en) *	1987-11-06	2000-11-07	Washington Research Foundation	Sandwich immunoassays for collagen type II degradation products
US6153732A (en) *	1987-11-06	2000-11-28	Washington Research Foundation	Kit for detecting analyte indicative of type II collagen resorption in vivo

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08100000A (ja) *	1994-09-30	1996-04-16	Morinaga & Co Ltd	ヒトｉｖ型コラーゲンに対する抗体及びその利用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH642458A5 (en) *	1980-04-25	1984-04-13	Hoffmann La Roche	Immunological method
JPS57208458A (en) *	1981-06-18	1982-12-21	Mitsui Toatsu Chem Inc	Labeled antibody for immunochemical measurement

1986
- 1986-09-04 JP JP61206862A patent/JPH0638081B2/ja not_active Expired - Lifetime
1987
- 1987-02-27 CA CA 530844 patent/CA1287801C/fr not_active Expired - Fee Related

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5834221A (en) *	1987-11-06	1998-11-10	Washington Research Foundation	Assay for type I collagen carboxy-terminal telopeptide analytes
US5939274A (en) *	1987-11-06	1999-08-17	Washington Research Foundation	Methods of monitoring patient responses to anti-resorptive therapies
US6027903A (en) *	1987-11-06	2000-02-22	Washington Research Foundation	Kit for detecting analyte indicative of type I collagen resorption in vivo
US6143511A (en) *	1987-11-06	2000-11-07	Washington Research Foundation	Sandwich immunoassays for collagen type II degradation products
US6153732A (en) *	1987-11-06	2000-11-28	Washington Research Foundation	Kit for detecting analyte indicative of type II collagen resorption in vivo
US6204367B1 (en)	1987-11-06	2001-03-20	Washington Research Foundation	Elisa kit for quantification of C-terminal telopeptides of type I collagen in human serum
US6509450B2 (en)	1987-11-06	2003-01-21	Washington Research Foundation	Immunoassay for quantification of C-terminal telopeptides of type I collagen in human serum

Also Published As

Publication number	Publication date
JPH0638081B2 (ja)	1994-05-18
JPS6363971A (ja)	1988-03-22

Legal Events

Date	Code	Title	Description
2005-08-22	MKLA	Lapsed

Publication	Publication Date	Title
US4797473A (en)	1989-01-10	Monoclonal antibodies to unreduced, nonenzymatically-glycated proteins
CA2008360A1 (fr)	1990-07-23	Essai immunologique pour le diagnostic de l'infarctus du myocarde
US5767247A (en)	1998-06-16	Anti-annexin-V monoclonal antibodies, and preparation and use thereof
JPH0720437B2 (ja)	1995-03-08	モノクロナ−ル抗体
US5316914A (en)	1994-05-31	Method for determining human collagen peptides by way of enzyme immunoassay
CA2274776C (fr)	2008-11-25	Procede d'analyse de l'annexine v dans l'urine et utilisation
US5670328A (en)	1997-09-23	Monoclonal antibodies to human pulmonary surfactant apoprotein D and use thereof
JP3018110B2 (ja)	2000-03-13	モノクローナル抗体
CA1287801C (fr)	1991-08-20	Methode de dosage des peptides du collagene humain par immunoessai enzymatique
US5298393A (en)	1994-03-29	Monoclonal antibody for human acid-glutathione S-transferase and process for preparation thereof
WO1992013096A1 (fr)	1992-08-06	Anticorps monoclonal anti-stromelysine humaine et diagnostic de l'arthrite rhumatoïde par immunoanalyse enzymatique
EP0401370B1 (fr)	1995-05-24	Analyse immunologique enzymatique selon un procedure en sandwich du collagene humain de type iv
JP4164804B2 (ja)	2008-10-15	酒石酸抵抗性酸性ホスファターゼ５ｂに特異的なモノクローナル抗体およびその用途
CA2281262C (fr)	2010-08-31	Anticorps monoclonal anti-medullasine humaine, processus de production et dosage immunologique utilisant cet anticorps moinoclonal
JP3076640B2 (ja)	2000-08-14	ヒト９２ｋＤａゼラチナーゼの免疫学的定量法
EP0314338A1 (fr)	1989-05-03	Méthode de mesure de l'insuline humaine
US5137807A (en)	1992-08-11	Method for determining beta-subunit of human prolyl 4-hydroxylase by immunoassay to detect hepatic disease
JP2609858B2 (ja)	1997-05-14	コラゲナーゼインヒビターの酵素免疫学的定量法
RU2210074C2 (ru)	2003-08-10	Иммунологический анализ человеческого медуллазина и диагностика рассеянного склероза с его помощью
JPH0677017B2 (ja)	1994-09-28	ヒト▲ｉｖ▼型コラーゲンのサンドイツチ酵素免疫学的定量法
EP0193935B1 (fr)	1992-07-22	Procédé de détermination de la prolyl 4-hydroxylase humaine par dosage immunologique
EP0339097B1 (fr)	1994-08-03	Methode de diagnostic du cancer du foie
US5130233A (en)	1992-07-14	Method for determining the β-subunit of human prolyl hydroxylase by radioimmunoassay to detect hepatic disease
JP2617783B2 (ja)	1997-06-04	肝臓癌疾患の診断用試薬
JP2609908B2 (ja)	1997-05-14	慢性関節リウマチ疾患の診断用試薬